Cell/Gene Tx channel feed

Gene ther­a­py biotech Splice­Bio gets $135M short­ly af­ter start­ing first clin­i­cal tri­al

2 days ago
Financing
Startups

Ver­tex lays off 125 work­ers af­ter type 1 di­a­betes cell ther­a­py failed study in March

2 days ago
People
Pharma

FDA's Makary looks at ways to speed drug ap­provals, talks about cut­ting user fees

Last week
FDA+

Trump's health ap­pointees pledge sup­port for cell and gene ther­a­pies at FDA round­table

Last week
FDA+

Re­genxbio says Duchenne gene ther­a­py im­proved mo­tor skills in five pa­tients

Last week
R&D

In a first, Sarep­ta an­nounces plat­form tech­nol­o­gy des­ig­na­tion for gene ther­a­py vec­tor

Last week
FDA+

At AS­CO, cell ther­a­pies for dead­ly form of brain can­cer make ear­ly strides

Last week
R&D

Im­mat­ics re­ports more ear­ly-stage da­ta for melanoma cell ther­a­py with piv­otal tri­al un­der­way

Last week
R&D

Up­dat­ed: Pa­tient dies in Rock­et gene ther­a­py tri­al, which is put on clin­i­cal hold by FDA

3 weeks ago
FDA+

CRISPR Ther­a­peu­tics part­ners with siR­NA com­pa­ny, show­ing that gene edit­ing isn’t the on­ly an­swer

4 weeks ago
R&D

Retro Bio­sciences inks blood dis­or­der deal as Sam Alt­man-backed biotech seeks $1B in funds

4 weeks ago
Startups
Deals

Prime Med­i­cine side­lines on­ly clin­i­cal pro­gram, re­places CEO and lays off some staff

4 weeks ago
People
R&D

In­tel­li­a's CRISPR ther­a­py like­ly caus­es 'per­ma­nen­t' gene knock­down in AT­TR amy­loi­do­sis

4 weeks ago
R&D
Pharma

David Liu, Sam Stern­berg un­veil new way to in­sert big genes in hu­man cells

4 weeks ago
R&D

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

4 weeks ago
R&D

In three pa­tients, Rock­et’s sec­ond heart gene ther­a­py shows promise

4 weeks ago
R&D

Eli Lil­ly turns to South Ko­re­an RNA edit­ing biotech for hear­ing loss in deal worth $1.3B

5 weeks ago
Startups
Deals

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

5 weeks ago
R&D
In Focus

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

5 weeks ago
R&D

CRISPR patent spat re­vived by fed­er­al ap­peals court rul­ing

Last month
Law

Up­dat­ed: To spin off or not to spin off? Gala­pa­gos backpedals on sep­a­ra­tion plans, CEO Paul Stof­fels ex­its ear­ly

Last month
People

Ex­clu­sive: Patrick Hsu start­up launch­es, looks be­yond CRISPR for gene in­ser­tion tech­nol­o­gy

Last month
Startups

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

Last month
R&D
In Focus

CRISPR Ther­a­peu­tic­s' gene edit­ing ther­a­py re­duces bad cho­les­terol and triglyc­erides by as much as 80%

Last month
R&D
1234 Next page Last page
A service from the Financial Times